

Form 604Corporations Act 2001
Section 671B**Notice of change of interests of substantial holder**To Company Name/Scheme Holista Colltech LimitedACN/ARSN 094 515 992**1. Details of substantial holder(1)**Name Dr Rajen Manicka

ACN/ARSN (if applicable) _____

There was a change in the interests of the substantial holder on

see attached table

The previous notice was given to the company on

15 / 7 / 2009

The previous notice was dated

10 / 7 / 2009**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Fully paid ordinary shares	77,000,000	71.48%	85,735,272	31.14%

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
See attached table					

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
See attached table					

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Galen Biomedical Inc	An entity controlled by Dr Manicka

6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Galen Biomedical Inc	1771, POST ROAD EAST #178, WESPORT CT 06880, UNITED STATES OF AMERICA USA

Signature



print name Dr Rajen Manicka

capacity

sign here

date 31 / 3 / 2021

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

Attachment to form 604

Item 3 - Changes in relevant interest

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
6/Aug/09	Dr Manicka	Dilution	N/A	N/A	-3.16%
14/Oct/09	Dr Manicka	Dilution	N/A	N/A	-5.47%
6/Nov/09	Dr Manicka	Dilution	N/A	N/A	0.001%
19/Nov/09	Dr Manicka	Dilution	N/A	N/A	-3.34%
5/Jan/11	Dr Manicka	Purchase	\$5,910	39,400 FPO shares	0.03%
10/Oct/13	Dr Manicka	Disposal	\$218,750.00	(3,125,000) FPO shares	-2.41%
17/Dec/13	Dr Manicka	Dilution	N/A	N/A	-4.71%
25/Sep/14	Dr Manicka	Dilution	N/A	N/A	-4.33%
23/Oct/15	Dr Manicka	Dilution	N/A	N/A	-1.26%
1/Apr/16	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(3)(b)	See notice of meeting dated 23 October 2015[●].	58,514,245 FPO shares	0.00%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
8/Mar/16	Dr Manicka	Dilution	N/A	N/A	-1.14%
8/Apr/16	Dr Manicka	Dilution	N/A	N/A	-0.14%
8/Apr/16	Dr Manicka	Dilution	N/A	N/A	-1.55%
28/Apr/16	Dr Manicka	Dilution	N/A	N/A	-0.31%
18/Aug/16	Dr Manicka	Dilution	N/A	N/A	-0.47%
18/Aug/16	Dr Manicka	Dilution	N/A	N/A	-0.08%
24/Mar/17	Dr Manicka	Dilution	N/A	N/A	-1.46%
18/Apr/17	Dr Manicka	Dilution	N/A	N/A	-0.39%
15/Jun/17	Dr Manicka	Dilution	N/A	N/A	-0.38%
26/Sep/17	Dr Manicka	Dilution	N/A	N/A	-0.34%
6/Oct/17	Dr Manicka	Dilution	N/A	N/A	-0.33%
12/Feb/18	Dr Manicka	Dilution	N/A	N/A	-1.37%
6/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.67%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
7/Aug/18	Dr Manicka	Acquisition (Underwritten SPP)	\$362,661.04	5,180,872 FPO shares	1.12%
10/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.78%
13/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.16%
24/Aug/18	Dr Manicka	Dilution	N/A	N/A	-0.54%
6/Sep/18	Dr Manicka	Dilution	N/A	N/A	-0.53%
28/Sep/18	Dr Manicka	Acquisition (Underwritten SPP)	\$208,772.13	2,982,459 FPO shares	0.84%
1/Nov/18	Dr Manicka	Off-market sale	\$70,000.00	1,000,000 FPO shares	-0.43%
1/Nov/18	Dr Manicka	Off-market sale	\$35,000.00	500,000 FPO shares	-0.21%
15/Jan/20	Dr Manicka	Dilution	N/A	N/A	-0.06%
24/Jan/19	Dr Manicka	Off-market sale	\$103,772.13	1,482,459 FPO shares	-0.63%
31/Jan/19	Dr Manicka	Acquisition	\$2,600	50,000 FPO shares	0.02%
1/Feb/19	Dr Manicka	Acquisition	\$12,562.82	228,415 FPO shares	0.10%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
5/Feb/19	Dr Manicka	Acquisition	\$3,387.17	61,585 FPO shares	0.03%
11/Feb/20	Dr Manicka	Dilution	N/A	N/A	-1.65%
19/Feb/20	Dr Manicka	Dilution	N/A	N/A	-1.50%
4/Mar/20	Dr Manicka	Dilution	N/A	N/A	-1.21%
25/Mar/20	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(1)(c)	Funds available under a non-recourse loan and springing securities pledge agreement dated 24 March 2020	20,541,627 FPO shares	0%
3/Apr/20	Dr Manicka	Acquisition (performance share)	See notice of meeting announced 2 December 2016 for details of the performance rights, the conversion of which resulted in the acquisition of FPO shares[●]	6,300,000 FPO shares	1.79%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
3/Apr/20	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(1)(c)	Funds available under a non-recourse loan and springing securities pledge agreement dated 24 March 2020	6,300,000 FPO shares	0%

Item 4 - present relevant interest

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder	Nature of relevant interest	Class and number of securities	Person's votes
Dr Manicka	Galen Biomedical	Galen Biomedical	Relevant interest by reason of sections 608(1)(b) and 608(1)(c) of the Corporations Act	58,514,245 FPO shares	58,514,245
Dr Manicka		Dr Manicka	Relevant interest by reason of section 608(1)(c) of the Corporations Act	26,841,627 FPO shares	0

Attachment to form 604

Item 3 - Changes in relevant interest

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
6/Aug/09	Dr Manicka	Dilution	N/A	N/A	-3.16%
14/Oct/09	Dr Manicka	Dilution	N/A	N/A	-5.47%
6/Nov/09	Dr Manicka	Dilution	N/A	N/A	0.001%
19/Nov/09	Dr Manicka	Dilution	N/A	N/A	-3.34%
5/Jan/11	Dr Manicka	Purchase	\$5,910	39,400 FPO shares	0.03%
10/Oct/13	Dr Manicka	Disposal	\$218,750.00	(3,125,000) FPO shares	-2.41%
17/Dec/13	Dr Manicka	Dilution	N/A	N/A	-4.71%
25/Sep/14	Dr Manicka	Dilution	N/A	N/A	-4.33%
23/Oct/15	Dr Manicka	Dilution	N/A	N/A	-1.26%
1/Apr/16	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(3)(b)	See notice of meeting dated 23 October 2015.	58,514,245 FPO shares	0.00%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
8/Mar/16	Dr Manicka	Dilution	N/A	N/A	-1.14%
8/Apr/16	Dr Manicka	Dilution	N/A	N/A	-0.14%
8/Apr/16	Dr Manicka	Dilution	N/A	N/A	-1.55%
28/Apr/16	Dr Manicka	Dilution	N/A	N/A	-0.31%
18/Aug/16	Dr Manicka	Dilution	N/A	N/A	-0.47%
18/Aug/16	Dr Manicka	Dilution	N/A	N/A	-0.08%
24/Mar/17	Dr Manicka	Dilution	N/A	N/A	-1.46%
18/Apr/17	Dr Manicka	Dilution	N/A	N/A	-0.39%
15/Jun/17	Dr Manicka	Dilution	N/A	N/A	-0.38%
26/Sep/17	Dr Manicka	Dilution	N/A	N/A	-0.34%
6/Oct/17	Dr Manicka	Dilution	N/A	N/A	-0.33%
12/Feb/18	Dr Manicka	Dilution	N/A	N/A	-1.37%
6/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.67%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
7/Aug/18	Dr Manicka	Acquisition (Underwritten SPP)	\$362,661.04	5,180,872 FPO shares	1.12%
10/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.78%
13/Aug/18	Dr Manicka	Dilution	N/A	N/A	-1.16%
24/Aug/18	Dr Manicka	Dilution	N/A	N/A	-0.54%
6/Sep/18	Dr Manicka	Dilution	N/A	N/A	-0.53%
28/Sep/18	Dr Manicka	Acquisition (Underwritten SPP)	\$208,772.13	2,982,459 FPO shares	0.84%
1/Nov/18	Dr Manicka	Off-market sale	\$70,000.00	1,000,000 FPO shares	-0.43%
1/Nov/18	Dr Manicka	Off-market sale	\$35,000.00	500,000 FPO shares	-0.21%
15/Jan/20	Dr Manicka	Dilution	N/A	N/A	-0.06%
24/Jan/19	Dr Manicka	Off-market sale	\$103,772.13	1,482,459 FPO shares	-0.63%
31/Jan/19	Dr Manicka	Acquisition	\$2,600	50,000 FPO shares	0.02%
1/Feb/19	Dr Manicka	Acquisition	\$12,562.82	228,415 FPO shares	0.10%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
5/Feb/19	Dr Manicka	Acquisition	\$3,387.17	61,585 FPO shares	0.03%
11/Feb/20	Dr Manicka	Dilution	N/A	N/A	-1.65%
19/Feb/20	Dr Manicka	Dilution	N/A	N/A	-1.50%
4/Mar/20	Dr Manicka	Dilution	N/A	N/A	-1.21%
25/Mar/20	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(1)(c)	Funds available under a non-recourse loan and springing securities pledge agreement dated 24 March 2020	20,541,627 FPO shares	0%
3/Apr/20	Dr Manicka	Acquisition (performance share)	See notice of meeting announced 2 December 2016 for details of the performance rights, the conversion of which resulted in the acquisition of FPO shares	6,300,000 FPO shares	1.79%

Date	Person whose relevant interest changed	Nature of change	Consideration given for the change	Class and number of securities affected	Person's affected votes
3/Apr/20	Dr Manicka	Disposal of interest arising by reason of section 606(1)(a) and acquisition by reason of section 606(1)(c)	Funds available under a non-recourse loan and springing securities pledge agreement dated 24 March 2020	6,300,000 FPO shares	0%

Item 4 - present relevant interest

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder	Nature of relevant interest	Class and number of securities	Person's votes
Dr Manicka	Galen Biomedical	Galen Biomedical	Relevant interest by reason of sections 608(1)(b) and 608(1)(c) of the Corporations Act	58,514,245 FPO shares	58,514,245
Dr Manicka		Dr Manicka	Relevant interest by reason of section 608(1)(c) of the Corporations Act	26,841,627 FPO shares	0